Drugs / MUPADOLIMAB
MUPADOLIMAB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04464395 | Jul 2020 → Mar 2021 | COVID-19 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03454451 | Apr 2018 → Dec 2022 | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04734873 | Feb → Aug 2021 | COVID-19 | Corvus Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUPADOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802200 ↗ |
| Known as | CPI-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04464395 ↗ |
| Known as | CPX-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802200 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody” NCT04464395 ↗ |
| Route | Intravenous | “Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days” NCT03454451 ↗ |